Esmo gi data: agenus' botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer

Lexington, mass.--(business wire)--immuno-oncology leader, agenus (nasdaq: agen), shared promising data today from its phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 esmo world congress on gastrointestinal cancer (esmo gi). the new data show substantial survival benefits and long-lasting responses for patients with non-msi-h (microsatellite stable or non-microsatellite instability-high) metastatic colorectal cancer previously resistant to c.
AGEN Ratings Summary
AGEN Quant Ranking